Search results

4350 results

Sorted by Relevance . Sort by Date

  1. Non-Hodgkin's lymphoma

    Everything NICE has said on diagnosing and managing non-Hodgkin's lymphoma in adults and young people 16 years and older in an interactive flowchart

  2. Spondyloarthritis

    Everything NICE has said on diagnosing and managing spondyloarthritis in people aged 16 and over in an interactive flowchart

  3. Respiratory conditions

    Everything NICE has said on respiratory conditions in an interactive flowchart

  4. Atrial fibrillation

    Everything NICE has said on diagnosing and managing atrial fibrillation in an interactive flowchart

  5. Osteoporosis

    Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

  6. Structural heart defects

    Everything NICE has said on structural heart defects in an interactive flowchart

  7. Autism spectrum disorder

    Everything NICE has said on recognition, referral, diagnosis and management of autism in an interactive flowchart

  8. Smoking

    Everything NICE has said on preventing the uptake of smoking and helping people to stop smoking in an interactive flowchart

  9. Twin and triplet pregnancy

    Everything NICE has said on managing twin and triplet pregnancies in the antenatal and intrapartum period in an interactive flowchart

  10. Barrett's oesophagus

    Everything NICE has said on treating adults with Barrett's oesophagus who have high-grade dysplasia or early intramucosal cancer in an interactive flowchart

  11. Gallstone disease

    Everything NICE has said on diagnosing and managing gallstone disease in adults in an interactive flowchart

  12. Ectopic pregnancy and miscarriage

    Everything NICE has said on diagnosing and managing tubal ectopic pregnancy and miscarriage in early pregnancy in an interactive flowchart.

  13. Donor breast milk banks

    Everything NICE has said on the operation of donor breast milk bank services in an interactive flowchart

  14. Colonoscopic surveillance

    Everything NICE has said on colonoscopic surveillance for people with inflammatory bowel disease or adenomas in an interactive flowchart.

  15. Sedation in children and young people

    Everything NICE has said on sedation for diagnostic and therapeutic procedures in infants, children and young people in an interactive flowchart

  16. Liver cancers

    Everything NICE has said on liver and bile duct cancers in an interactive flowchart

  17. Alcohol-use disorders

    Everything NICE has said on preventing, diagnosing and managing alcohol-related disorders in an interactive flowchart

  18. Non-alcoholic fatty liver disease

    Everything NICE has said on diagnosing and managing non-alcoholic fatty liver disease and advanced liver fibrosis in an interactive flowchart

  19. Cirrhosis

    Everything NICE has said on assessing and managing suspected or confirmed cirrhosis in people over 16 in an interactive flowchart

  20. Multiple sclerosis

    Everything NICE has said on multiple sclerosis in an interactive flowchart

  21. Neonatal jaundice

    Everything NICE has said on diagnosing and treating jaundice in newborn babies under 28 days in an interactive flowchart

  22. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    The purpose of this guideline is to provide recommendations for managing COVID-19 symptoms for patients in the community, including at the end of life. It also includes recommendations about managing medicines for these patients, and protecting staff from infection.

  23. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    The purpose of this guideline is to help healthcare professionals prevent, detect and manage acute kidney injury in adults in hospital with known or suspected COVID-19. This is important to improve outcomes and reduce the need for renal replacement therapy.

  24. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172)

    The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  25. COVID-19 rapid guideline: critical care in adults (NG159)

    The purpose of this guideline is to maximise the safety of patients who need critical care during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  26. COVID-19 rapid guideline: delivery of radiotherapy (NG162)

    The purpose of this guideline is to maximise the safety of patients who need radiotherapy and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for radiotherapy to patient needs if services become limited because of the COVID-19 pandemic.

  27. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  28. COVID-19 rapid guideline: severe asthma (NG166)

    The purpose of this guideline is to maximise the safety of adults and children with severe asthma during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  29. COVID-19 rapid guideline: cystic fibrosis (NG170)

    The purpose of this guideline is to maximise the safety of patients with cystic fibrosis and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match capacity to patient needs if services become limited because of the COVID-19 pandemic.

  30. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NG169)

    The purpose of this guideline is to maximise the safety of children and adults who have dermatological conditions treated with drugs affecting the immune response during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  31. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    The purpose of this guideline is to ensure the best treatment for adults with suspected or confirmed pneumonia in the community during the COVID-19 pandemic and best use of NHS resources. We have withdrawn our guideline on diagnosing and managing pneumonia in adults until further notice. For general advice on managing COVID-19 symptoms, see the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life) in the community .

  32. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  33. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  34. COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)

    The purpose of this guideline is to maximise the safety of patients with cancer and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for cancer treatment to patient needs if services become limited because of the COVID-19 pandemic.

  35. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168)

    The purpose of this guideline is to maximise the safety of patients with chronic obstructive pulmonary disease (COPD) during the COVID-19 pandemic, while protecting staff from infection. It will also enable services to make the best use of NHS resources.

  36. COVID-19 rapid guideline: acute myocardial injury (NG171)

    The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease.

  37. COVID-19 rapid guideline: dialysis service delivery (NG160)

    The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.

  38. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  39. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection. It will also enable services to match the capacity for transplantation to patient needs if services become limited because of the COVID-19 pandemic.